COMP <GO>
TSHA vs LYCA // EV/EBITDA & P/E VALUATION
Taysha Gene Therapies Inc. (NASDAQ) VS. Lycia Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TSHA 0
— LYCA 2
■ METRIC PARITY
LAST: $4.22 (-0.24%) • MKT CAP: $1.38B
valuation
—
LAST: $27.73 (+10.70%) • MKT CAP: $1.44B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TSHA VS. LYCA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TSHA | LYCA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.82% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 17.30% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.67 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.8 | 82.2 | -38.44 | LYCA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.38B | $1.44B | -$69.6M | LYCA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TSHA REV | LYCA REV | TSHA GROSS % | LYCA GROSS % | TSHA FCF | LYCA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.8M | — | — | — | -$93.8M | — |
| FY 2024 | $8.3M | — | — | — | -$81.6M | — |
| FY 2023 | $15.5M | — | — | — | -$73.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TSHA // BETA —
LYCA // BETA —